EUVIMEDEUVIMED entdecken
Crossref

Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials

Callie D McAdams, Nicholas Clevenger, Kyra Nicholson, Catherine Pesce, Katherine Kopkash, Elizabeth Poli, Thomas W Smith, Katherine Yao

Journal of Surgical Oncology · 2025

DOI: 10.1002/jso.27858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Callie D McAdams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, NorthShore University Healthsystem, Evanston, Illinois, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Patient Selection, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COMET, LORD, and LORIS clinical trials are investigating the role of active surveillance in low‐risk ductal carcinoma in situ (DCIS). The objective of this study was to identify the proportion of patients eligible for these trials amongst a cohort of patients treated at our institution.

Methods

Retrospective chart review was performed of patients diagnosed with DCIS who were treated from 2013 to 2022. Clinical, tumor, and imaging inclusion and exclusion criteria of the aforementioned observation trials were applied to determine the proportion of patients eligible for each trial. Upgrade rate to invasive cancer were examined across all three groups.

Results

Of 1223 patients diagnosed with DCIS, applying the criteria of each trial, 245 (20%), 238 (19.4%), and 264 (21.6%) patients were eligible for the COMET, LORD, and LORIS trials, respectively. High‐grade DCIS and mass on imaging had the largest impact on exclusion. Nineteen (7.8%) of women who qualified for COMET were upgraded to invasive disease at excision, compared to 18 (7.6%) for LORD, and 19 (7.2%) for LORIS.

Conclusions

One in five patients diagnosed with DCIS at our institution would qualify for observation with current trial eligibility. Observation of DCIS may have limited impact on all DCIS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingPatient SelectionClinical Trials as TopicWatchful WaitingHumansFemaleRetrospective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

active surveillanceductal carcinoma in situobservation

Autor:innen und Institutionen

  • Department of Surgery, NorthShore University Healthsystem, Evanston, Illinois, USA.

Zitieren

APA

McAdams, C. D., Clevenger, N., Nicholson, K., Pesce, C., Kopkash, K., Poli, E., Smith, T. W., & Yao, K. (2025). Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27858

Vancouver

McAdams CD, Clevenger N, Nicholson K, Pesce C, Kopkash K, Poli E, et al. Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials. Journal of Surgical Oncology. 2025. doi:10.1002/jso.27858

BibTeX
@article{McAdams2025,
  author = {McAdams, Callie D and Clevenger, Nicholas and Nicholson, Kyra and Pesce, Catherine and Kopkash, Katherine and Poli, Elizabeth and Smith, Thomas W and Yao, Katherine},
  title = {Proportion of Patients With Ductal Carcinoma In Situ That Qualify for Observation Criteria Set Forth by Clinical Trials},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1002/jso.27858}
}
Kostenlos starten →